Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Total Liabilities (2016 - 2025)

Syndax Pharmaceuticals has reported Total Liabilities over the past 11 years, most recently at $465.1 million for Q4 2025.

  • Quarterly results put Total Liabilities at $465.1 million for Q4 2025, up 6.5% from a year ago — trailing twelve months through Dec 2025 was $465.1 million (up 6.5% YoY), and the annual figure for FY2025 was $465.1 million, up 6.5%.
  • Total Liabilities for Q4 2025 was $465.1 million at Syndax Pharmaceuticals, up from $436.4 million in the prior quarter.
  • Over the last five years, Total Liabilities for SNDX hit a ceiling of $465.1 million in Q4 2025 and a floor of $21.6 million in Q3 2022.
  • Median Total Liabilities over the past 5 years was $48.1 million (2021), compared with a mean of $141.8 million.
  • Biggest five-year swings in Total Liabilities: plummeted 48.98% in 2023 and later soared 929.65% in 2025.
  • Syndax Pharmaceuticals' Total Liabilities stood at $41.3 million in 2021, then dropped by 27.86% to $29.8 million in 2022, then skyrocketed by 97.01% to $58.7 million in 2023, then skyrocketed by 644.14% to $436.7 million in 2024, then rose by 6.5% to $465.1 million in 2025.
  • The last three reported values for Total Liabilities were $465.1 million (Q4 2025), $436.4 million (Q3 2025), and $438.7 million (Q2 2025) per Business Quant data.